Prostate Cancer DNA Vaccine Results In Higher T-Cell Response When Delivered Via Inovio Biomedical’s Electroporation Delivery System

Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced that the team of Dr. Christian H. Ottensmeier, MD, PhD, Cancer Research UK Senior Clinical Research Fellow at the University of Southampton, will present interim data from a clinical study of an experimental DNA-based prostate cancer vaccine at the American Association for Cancer Research meeting in San Diego, USA, April 12 - 16, 2008.

More: continued here

Filed under: Immune System / Vaccines on April 8th, 2008